Opinion

Video

Challenges of PSA as a Diagnostic Biomarker

Author(s):

Benjamin H. Lowentritt, MD, FACS,Brian Richardson, MD

The key opinion leaders explore the challenges and limitations associated with using prostate-specific antigen (PSA) as a biomarker for prostate cancer detection and monitoring.

Video content above is prompted by the following question:

  • What are some challenges or limitations in using PSA as a biomarker?
Related Videos
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Dr Louise Kostos answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Related Content
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
April 25th 2025

FDA clears AI-powered application for measuring prostate volume

Benjamin P. Saylor
Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Welcome to Fabulous Las Vegas Neon Sign | Image Credit: © somchaij - stock.adobe.com
April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke
We preview several noteworthy P2 presentations in the urologic oncology space.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
3d rendered medically accurate illustration of prostate cancer | Image Credit: @ Sebastian Kaulitzki - stock.adobe.com
April 15th 2025

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

Hannah Clarke
The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.
Study underway to assess 3-fraction SBRT regimen in prostate cancer
April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke
"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.
© 2025 MJH Life Sciences

All rights reserved.